(This is incredibly good medicine)
The assessment of vascular dysfunction and autonomic nervous system dysfunction both
are health risk factors for atherosclerosis. They both are well-recognized tests to detect
early complications in diabetic patients – diabetic neuropathy risk, cardiovascular risk,
and peripheral artery disease. The U.S. and International Medical Associations
recommend these assessments. Through the Autonomic nervous system, endothelial
dysfunction affects the pathological process during a condition of hypertension. The
neuroanatomy process has an interrelationship between autonomic neuropathy of
diabetes mellitus with vascular dysfunction.
When the autonomic nervous system (ANS ) and endothelial functions are correctly working, the
patient is in good health and has a high potential for recovery.
When one of the regulation’s functions fails or is stressed beyond its genetic potential for different reasons - inadequate lifestyle, aging, weak genetics, then disease may occur.
Lab tests show the damage of the regulation functions when the disease is already onset. We could detect a potential future disease early when the treatment options can delay or reverse a condition or disease by assessing the regulatory functions.
The conventional exams cannot detect Cardiac Autonomic Neuropathy (CAN ) or endothelial dysfunction symptoms, and patients suffering from these symptoms cannot be treated effectively.
When a disease is diagnosed, the treatment management should control the disease diagnosis marker and restore or maintain the regulations’ functions: Autonomic nervous system and endothelial functions.
AUTONOMOUS NERVOUS SYSTEM DYSFUNCTION RISK - ANSD
Problems with the ANS can range from mild to life-threatening. Sometimes, only one part of the
nervous system is affected. In other cases, the entire ANS is involved. Some conditions are
temporary and can be reversed, while others are chronic and worsen over time. Diseases such as
diabetes or Parkinson’s Disease can cause irregularities with ANS. Problems with ANS regulation
often involve organ failure or the failure of the nerves to transmit a necessary signal.
SUDOMOTOR DYSFUNCTION RISK - SUDOD
Sudomotor dysfunction testing may indicate to physicians a patient's peripheral nerve and cardiac
sympathetic dysfunction. Neuropathy is a common complication in diabetes mellitus (DM), with
60%-70% of patients affected over their lifetime. Symptoms of neuropathy are more common than
clinical neuropathy. Neuropathy may remain undetected and progress over time, leading to severe
complications. The most common associated clinical condition is peripheral neuropathy, affecting
the feet. Autonomic nerve involvement is joint but probably the most undiagnosed. Low scores in the
sudomotor may lead a medical provider to look at clinical neuropathy.
ENDOTHELIAL DYSFUNCTION RISK - ENDOD
Current evidence suggests that endothelial function is an integrative marker of the net effects of
damage from traditional and emerging risk factors on the arterial wall and its intrinsic capacity for
repair. Endothelial dysfunction, detected as the presence of reduced vasodilating response to
endothelial stimuli, has been associated with major cardiovascular risk factors, such as aging,
hyperhomocysteinemia, post-menopause state, smoking, diabetes, hypercholesterolemia,
and hypertension.
INSULIN RESISTANCE RISK - IR
Insulin resistance is defined clinically as the inability of a known quantity of exogenous or
endogenous insulin to increase glucose uptake and utilization in an individual as it does in a normal
population. Insulin resistance occurs as part of a cluster of cardiovascular, metabolic abnormalities
commonly referred to as "The Insulin Resistance Syndrome" or "The Metabolic Syndrome". This
cluster of abnormalities may lead to Type-2 diabetes, accelerated atherosclerosis, hypertension, or
polycystic ovarian syndrome depending on the genetic background of the individual
developing insulin resistance.
CARDIOMETABOLIC RISK - CMR
The specific factors that can cause this increased risk include obesity (mainly central),
hyperglycemia, hypertension, insulin resistance, and dyslipoproteinemia. When patients have
oneor more risk factors and are physically inactive or smoke, the cardiometabolic risk is
increased even more. Medical conditions that often share the above characteristics, such as
type 2 diabetes, can also increase cardiometabolic risk. The primary focus of cardiometabolic
risk treatment is managing each high-risk factor, including dyslipoproteinemia, hypertension,
and diabetes. The management of these subjects is based principally on lifestyle
measures, but various antihypertensive, lipid-lowering, insulin-sensitizing,
anti-obesity, and antiplatelet drugs could help to reduce cardiometabolic risk.
SMALL FIBER NEUROPATHY RISK - SFN
A small fiber neuropathy occurs when damage to the peripheral nerves predominantly
or entirely affects the small myelinated fibers or unmyelinated C fibers. The specific
fiber types involved in this process include both tiny somatic and autonomic fibers.
The sensory functions of these fibers include thermal perception and nociception.
These fibers are involved in many autonomic and enteric functions.
CARDIAC AUTONOMIC NEUROPATHY RISK - CAN
High blood glucose levels over an Additional of the year may cause a condition called autonomic
neuropathy. This is damage to the nerves that control the regulation of involuntary function. When
nerve damage affects the heart, it is called cardiac autonomic neuropathy (CAN). CAN
encompasses damage to the autonomic nerve fibers that innervate the heart and blood vessels,
resulting in abnormalities in heart rate control, vascular dynamics, and the body's ability to adjust
blood pressure. CAN is a significant cause of morbidity and mortality associated with a high risk of
cardiac arrhythmias and sudden death.
PLETHYSMOGRAPHY CARDIOVASCULAR DISEASE RISK - PTG CVD
The PTG CVD risk factor is the combined total of the other seven risk factors assessments. Thus,
it considers the cardiovascular and the autonomic nervous system (ANS) measurements.
With our comprehensive and instructional ANS test reports, you will access credible testing criteria (based on validated medical markers). These criteria establish the medical necessity for over
21 validated additional tests for continued and accurate patient diagnosis!
Here are some examples of additional diagnostic tests
that our ANS Test results VALIDATE.
Testing to Determine Insulin Resistance and Glucose Tolerance Testing and/or A1C
Testing to Determine Insulin Resistance and Glucose Tolerance Testing and/or A1C
Small Fiber Neuropathy Testing and If Peak C is elevated Nerve Conduction Studies or Potentially CT W/Contrast and/or Ultrasound
Small Fiber Neuropathy Testing
Small Fiber Neuropathy Testing and If Peak C is elevated Nerve Conduction Studies or Potentially CT W/Contrast and/or Ultrasound
Small Fiber Neuropathy Testing
Copyright © -2024 Pece Portal. All Rights Reserved.